# Hesperetin, Acting Through Inhibition of c-Jun Signaling, Mitigates Hypomyelinating Disease-Associated Stop-Loss Claudin-11-Induced Defective Morphogenesis in Oligodendroglial FBD-102b Cells

**Authors:** Yuki Miyamoto, Takeru Omata, Yuta Muraki, Moeri Yagi, Masahiro Yamamoto, Akinori Nishi, Hideji Yako, Junji Yamauchi

PMC · DOI: 10.3390/ijms27041956 · 2026-02-18

## TL;DR

Hesperetin helps fix cell development issues caused by a genetic mutation linked to a brain myelin disorder.

## Contribution

First demonstration that hesperetin mitigates stop-loss CLDN11 mutation effects via c-Jun inhibition in oligodendroglial cells.

## Key findings

- CLDN11 stop-loss mutation reduces oligodendroglial differentiation markers and process extension.
- Mutant CLDN11 induces ER stress and activates JNK and eIF2A kinases.
- Hesperetin recovers differentiation by inhibiting c-Jun signaling and reducing ER stress.

## Abstract

Hypomyelinating leukodystrophies (HLDs) are a group of hereditary CNS disorders characterized by hypomyelination and, sometimes, repeated cycles of demyelination and remyelination. In HLDs, various genetic mutations in the responsible genes disrupt the morphogenesis of oligodendrocytes (oligodendroglial cells), which wrap neuronal axons with their differentiated myelin sheaths. A stop-loss mutation (c.622T-C or c.622T-G) in the gene encoding claudin family tetraspan plasma membrane protein claudin-11 (CLDN11) is associated with HLD22, which is characterized by incomplete differentiation and hypomyelination or delayed myelination in the brain. Herein, we describe for the first time that a CLDN11 mutant protein with an additional amino acid sequence due to the stop-loss mutation, but not the wild-type protein, leads to decreased expression of oligodendroglial differentiation marker proteins in the FBD-102b oligodendroglial progenitor cell line, the model undergoing its differentiation, at both the molecular and morphological levels. Consistently, mutant CLDN11 exhibited decreased morphological differentiation with a reduced ability to extend processes. These cells contained punctate structures that were partially localized in the endoplasmic reticulum (ER) and stimulated phosphorylation of c-Jun N-terminal kinase (JNK) and eukaryotic translation initiation factor 2A (eIF2A) kinase, ER stress-responsible kinases. Hesperetin, a neuroprotective flavonoid that can downregulate ER stress, recovered the differentiation abilities of these cells. Notably, the effects were related to decreased phosphorylation of ER stress-responsible kinases. JNK was found to be present in a co-precipitate with the hesperetin core, whereby hesperetin inhibited signaling through c-Jun as a negative regulator of differentiation. These findings indicate that the HLD22-associated mutant protein can cause an ER stress response, decreasing cell morphological differentiation. In addition, this study offers possible therapeutic implications for the as-yet-unexplored mechanisms involved in HLD22, at least at the molecular and cellular levels.

## Linked entities

- **Genes:** CLDN11 (claudin 11) [NCBI Gene 5010]
- **Proteins:** Cldn11 (claudin 11), JUN (Jun proto-oncogene, AP-1 transcription factor subunit), MAPK8 (mitogen-activated protein kinase 8), EIF2A (eukaryotic translation initiation factor 2A)
- **Chemicals:** hesperetin (PubChem CID 3593)
- **Diseases:** HLD22 (MONDO:0025701)

## Full-text entities

- **Genes:** MBP (myelin basic protein) [NCBI Gene 4155], EIF2A (eukaryotic translation initiation factor 2A) [NCBI Gene 83939] {aka CDA02, EIF-2A, MST089, MSTP004, MSTP089}, RPS6KA1 (ribosomal protein S6 kinase A1) [NCBI Gene 6195] {aka HU-1, MAPKAPK1, MAPKAPK1A, RSK, RSK1, p90Rsk}, CLDN11 (claudin 11) [NCBI Gene 5010] {aka HLD22, OSP, OTM}, TJP1 (tight junction protein 1) [NCBI Gene 7082] {aka ZO-1}, SHROOM2 (shroom family member 2) [NCBI Gene 357] {aka APXL, HSAPXL}, DLG1 (discs large MAGUK scaffold protein 1) [NCBI Gene 1739] {aka DLGH1, SAP-97, SAP97, hdlg}, DLG4 (discs large MAGUK scaffold protein 4) [NCBI Gene 1742] {aka MRD62, PSD95, SAP-90, SAP90}, HSPA5 (heat shock protein family A (Hsp70) member 5) [NCBI Gene 3309] {aka BIP, GRP78, HEL-S-89n}, Cldn11 (claudin 11) [NCBI Gene 18417] {aka Claudin-11, Claudin11, Osp, Otm}, DDIT3 (DNA damage inducible transcript 3) [NCBI Gene 1649] {aka AltDDIT3, C/EBPzeta, CEBPZ, CHOP, CHOP-10, CHOP10}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, Fgf2 (fibroblast growth factor 2) [NCBI Gene 54250] {aka Fgf-2, Fgf2a, bFGF}, JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725] {aka AP-1, AP1, c-Jun, cJUN, p39}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, CCL14 (C-C motif chemokine ligand 14) [NCBI Gene 6358] {aka CC-1, CC-3, CKB1, HCC-1, HCC-1(1-74), HCC-1/HCC-3}, EIF2AK3 (eukaryotic translation initiation factor 2 alpha kinase 3) [NCBI Gene 9451] {aka PEK, PERK, WRS}, GJC2 (gap junction protein gamma 2) [NCBI Gene 57165] {aka CX46.6, Cx47, GJA12, HLD2, LMPH1C, LMPHM3}, MAPKAPK2 (MAPK activated protein kinase 2) [NCBI Gene 9261] {aka MAPKAP-K2, MK-2, MK2}, PLP1 (proteolipid protein 1) [NCBI Gene 5354] {aka GPM6C, HLD1, MMPL, PLP, PLP/DM20, PMD}
- **Diseases:** nystagmus (MESH:D009759), HLD types 1 and 2 (MESH:D003924), white matter hypoplasia (MESH:D056784), leukodystrophies (MESH:D007966), hereditary CNS disorders (MESH:D020271), spastic quadriplegia (MESH:D011782), Pelizaeus-Merzbacher disease (MESH:D020371), multiple sclerosis (MESH:D009103), brain developmental delay (MESH:D001927), ataxia (MESH:D001259), delayed myelination (MESH:D003711), hereditary CNS disorders (MESH:D009386), HLD22 (MESH:C536319), injury to (MESH:D014947), inflammation (MESH:D007249), Pelizaeus-Merzbacher-like disease (MESH:C563855)
- **Chemicals:** paraformaldehyde (MESH:C003043), NaF (MESH:D012969), Sepharose 4B (MESH:D012685), Hesperetin (MESH:C013015), ATP (MESH:D000255), CO2 (MESH:D002245), Flavonoids (MESH:D005419), DMSO (MESH:D004121), NaOH (MESH:D012972), DTT (MESH:D004229), PVDF (MESH:C024865), MnCl2 (MESH:C025340), SDS (MESH:D012967), aglycone (MESH:C458179), G418 (MESH:C010680), HEPES (MESH:D006531), flavanone (MESH:C028610), MgCl2 (MESH:D015636), J4110EPCG0-2 (-), leupeptin (MESH:C032854), trypan blue (MESH:D014343), methanol (MESH:D000432), NaCl (MESH:D012965), vitamin P (MESH:D012431), polyacrylamide (MESH:C016679), NP-40 (MESH:C010615), EDTA (MESH:D004492), hesperidin (MESH:D006569), F-12 (MESH:C007782)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** S73E, S63E, c.622T-G, Ser-to-Glu, p.Ala243Val, c.622T-G
- **Cell lines:** RCB4965 — Homo sapiens (Human), Myxofibrosarcoma, Cancer cell line (CVCL_4661), FBD-102b — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_C6DV), HLD22 — Mus musculus (Mouse), Hybridoma (CVCL_B4FN)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940162/full.md

---
Source: https://tomesphere.com/paper/PMC12940162